ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1594799
Efficacy and safety of leuprorelin (Boennuokang®) plus endocrine therapy in premenopausal women with HR+/HER2- breast cancer
Provisionally accepted
- Zhangzhou Zhengxing Hospital, Zhangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Leuprorelin shows good efficacy in premenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, more real-world evidence is required. This real-world study aimed to explore the efficacy and safety of leuprorelin (Boennuokang®) plus endocrine therapy in premenopausal women with HR+/HER2- breast cancer.Methods: A total of 229 premenopausal women with HR+/HER2- breast cancer receiving adjuvant leuprorelin plus endocrine therapy were included in this retrospective study. Leuprorelin (Boennuokang®) was administered 3.75 mg subcutaneously every 28 days following surgery. Endocrine therapy contained aromatase inhibitors, selective estrogen receptor modulators, and selective estrogen receptor degraders. The median follow-up duration of this study was 38.1 months.Results: The estradiol (E2) level was declined from 46.0 to 19.0 pg/mL over 24 months (P<0.001). E2 from month 3 to month 24 was maintained below 30 pg/mL (menopausal level). During 24 months, the follicle-stimulating hormone (FSH) level was decreased from 7.7 to 4.8 mIU/mL, and the luteinizing hormone (LH) level was decreased from 7.9 to 0.2 mIU/mL (both P<0.001). During the follow-up period, 9 patients experienced disease recurrence. The 10-year accumulating progression-free survival (PFS) rate was 91.7%. Comorbidity (yes vs. no) was independently related to shorter PFS (hazard ratio: 10.957, P=0.003). Bone soreness (6.1%) was the most common adverse event, followed by hot flushes (3.5%), morning stiffness (1.3%), and muscle soreness (1.3%).Conclusion: Leuprorelin (Boennuokang®) plus endocrine therapy reduces gonadotropins and sex hormones and results in satisfactory survival rates with good safety profiles in premenopausal women with HR+/HER2- breast cancer.
Keywords: Hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, Premenopausal women, leuprorelin (Boennuokang ® ), efficacy, Safety
Received: 17 Mar 2025; Accepted: 20 Jun 2025.
Copyright: © 2025 Wu, Lin, Xie, Jiang, Xu, He and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiuping Wu, Zhangzhou Zhengxing Hospital, Zhangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.